Figure 5.
Comparison of pretreatment tumor gene expression in patients with CR/PR and PD/NR. (A) Volcano plot showing the fold change and associated P values (Student t test) from a comparison of the expression of 132 selected genes in CR/PR vs PD/NR patients. The red dots represent genes found to be differentially expressed by predefined thresholds (log2 fold change >1 and false discovery rate (FDR)-corrected value of P < .2). (B) Baseline gene expression levels of CD30, PD-1, and PD-L1 among patients with different clinical activity. Gene expression is reported as counts per million sequenced reads. Boxes indicate the interquartile range, horizontal black lines indicate the median values, and the bars extend to the upper and lower adjacent values. FGF, fibroblast growth factor; GPR, G-protein–coupled receptor; HGF, hepatocyte growth factor; IRF, IFN-regulatory factor; NR, no response; ULBP, UL16-binding protein.

Comparison of pretreatment tumor gene expression in patients with CR/PR and PD/NR. (A) Volcano plot showing the fold change and associated P values (Student t test) from a comparison of the expression of 132 selected genes in CR/PR vs PD/NR patients. The red dots represent genes found to be differentially expressed by predefined thresholds (log2 fold change >1 and false discovery rate (FDR)-corrected value of P < .2). (B) Baseline gene expression levels of CD30, PD-1, and PD-L1 among patients with different clinical activity. Gene expression is reported as counts per million sequenced reads. Boxes indicate the interquartile range, horizontal black lines indicate the median values, and the bars extend to the upper and lower adjacent values. FGF, fibroblast growth factor; GPR, G-protein–coupled receptor; HGF, hepatocyte growth factor; IRF, IFN-regulatory factor; NR, no response; ULBP, UL16-binding protein.

Close Modal

or Create an Account

Close Modal
Close Modal